Thymogen

Thymogen is chemically synthesised glutamyl-tryptophan, identified as an active dipeptide motif within thymus extract. Russian pharmacological work describes it as increasing the number and functional activity of T-lymphocytes, normalising the T-helper to T-suppressor ratio, and enhancing phagocytosis and non-specific resistance to infection. It is also credited with accelerating regeneration in damaged tissue and improving cellular metabolism in wound models, which underpins its topical cream formulation. Mechanistically the receptor-level detail is thin - most of what exists is Soviet and post-Soviet pharmacology rather than modern molecular work, so treat the pathway claims as descriptive rather than mapped.

Targets: T-lymphocyte differentiation, T-helper/T-suppressor ratio, Phagocyte activity

• · The Russian label is 100 mcg once daily, total 300-1,000 mcg per course. This is the only properly specified dosing that exists for this compound.
• · The spray delivers 25 mcg per dose. Ten days for treatment, three to five days for prophylaxis during respiratory season.

Work out your exact syringe units →

• commonInjection-site discomfort— Intramuscular route; usually minor at these tiny doses.
• uncommonNasal irritation with the spray— Transient burning or dryness.
• rareAllergic reaction— Listed on the Russian label as the main contraindication trigger.

• Known hypersensitivity to the drug.
• Pregnancy and breastfeeding, per the Russian label.
• Autoimmune disease, on the general principle that immunostimulation is the wrong direction there.

• redundantvilon — Both are short thymic-derived dipeptides with overlapping claimed effects.
• redundantthymosin-alpha-1 — Same general target - T-cell maturation - with far weaker evidence behind Thymogen.

• · No routine bloodwork established; track infection frequency and recovery time as the practical endpoint.

Registered pharmaceutical in Russia and some CIS countries as injection, nasal spray and cream. Not approved in the US or EU; sold elsewhere as a research chemical.

• Russian State Register of Medicines entry for Thymogen (glutamyl-tryptophan) (label)
• Russian clinical literature on Glu-Trp dipeptide immunocorrection (other)

This is where honesty has to override the impulse to write something impressive. There is no receptor-level mechanism for Thymogen in the accessible international literature. What exists is descriptive Soviet and Russian pharmacology - increased T-lymphocyte number and function, normalised T-helper to T-suppressor ratio, enhanced phagocytosis, accelerated tissue regeneration - reported as findings rather than traced to a pathway. The one piece of independently published mechanistic work is Deigin's, which examined the effect of EW dipeptide isomers on the spleen colony-forming unit population in intact and irradiated mice, placing the activity somewhere in haematopoietic progenitor regulation. Semina's earlier work in the same tradition described synthetic peptides substituting for accessory T-lymphocytes in splenic haematopoietic colony formation. Taken together that suggests the compound acts on early haematopoietic and lymphoid progenitors rather than on mature T-cells, which would be consistent with the thymic-fragment framing. But no receptor has been identified, no signalling cascade has been mapped, and no binding data exist. Anyone presenting a detailed pathway diagram for Glu-Trp is drawing it from imagination.

The concrete, avoidable failure with this compound is a dosing error of two orders of magnitude. The Russian pharmacy product is a ready-made 100 mcg/mL solution; the research market sells 10 mg vials of Glu-Trp. Reconstituting 10 mg in 2 mL gives 5 mg/mL, which is fifty times the labelled clinical concentration, and a single 'unit' on a U-100 syringe from that vial is 50 mcg - meaning two units is a full labelled dose and anything approaching a normal-looking injection volume is a massive overdose relative to the only dosing that has ever been specified. A serial dilution step is mandatory, not optional. Beyond that the honest answer is that nobody knows what goes wrong, because the entire safety record is a Russian label listing hypersensitivity and pregnancy as the contraindications, with no Western regulatory review of any kind.

• Haematopoietic progenitor / spleen colony-forming unit population — No binding data exist

  Modulation of CFU-S numbers in intact and irradiated mice, with the effect differing between optical and chemical isomers. This is the closest thing to a defined target the compound has.

• T-lymphocyte differentiation (descriptive) — No receptor identified, no affinity data

  Reported increase in T-cell number and functional activity and normalisation of the T-helper to T-suppressor ratio. Reported, not mapped.

Minutes: the dipeptide is hydrolysed. Days 1-3: the registered nasal prophylaxis course is only three to five days long, which implies the manufacturer expects something within that window. Days 3-10: the registered treatment courses run this length, so this is the timescale on which any effect is claimed. Weeks and months: not applicable - this compound is not designed for continuous use and no long-term data exist.

There is nothing evidence-based to say here. Thymogen and Vilon are both minimal thymic-derived peptides with overlapping claims and running both is duplicative. Stacking Thymogen with thymosin alpha-1 is buying a well-evidenced compound and a poorly-evidenced one that claims the same endpoint - if the budget is fixed, spend it on the first. The nasal spray alongside a seasonal respiratory protocol is the one use with an internally coherent rationale, since it puts the peptide directly onto the mucosal lymphoid tissue it is supposed to act on.

Among the Russian bioregulator peptides, Thymogen is one of the better-documented - it has an actual state registration with a defined label, defined dose and defined course length, which is more than Crystagen has. That is a low bar. Against thymosin alpha-1 it is not a serious comparison: one has phase 3 data and 30 national approvals, the other has a domestic registration and two internationally indexed mechanistic papers. Against Vilon it is essentially a sibling - a two-residue peptide from thymus-extract research with overlapping claims - and the choice between them is arbitrary. The genuinely useful thing about Thymogen relative to the rest of the Khavinson-adjacent family is that the label specifies a real dose, so at least you know what you are supposed to be taking.

$20–$60/month. A single 10 mg research vial covers many 100 mcg courses if diluted correctly, so the true cost of a three to ten day course is low. The figure here reflects buying one vial per active period rather than a monthly recurring spend.

• ?No pharmacokinetic data of any kind exist for Glu-Trp in humans - not tmax, not bioavailability, not half-life, not clearance.
• ?No receptor or signalling pathway has been identified. The mechanism section of most vendor pages is invented.
• ?The supporting clinical literature is almost entirely Russian-language, largely unblinded and not indexed internationally. It could not be assessed directly in this session.
• ?Whether the intranasal route achieves any systemic exposure, or acts purely on nasal-associated lymphoid tissue, is unresolved.
• ?Deigin's isomer work implies stereochemistry matters, but research-market vendors typically do not specify optical purity. Whether what is sold is L-Glu-L-Trp is often unverifiable.
• ?Thymogen and Thymalin are frequently conflated in vendor material. They are different products - Thymalin is a bovine thymus extract, Thymogen is the synthetic Glu-Trp dipeptide.
• ?No human trial has been located that meets indexed publication standards, so the trials array is empty.

• The effects of the EW dipeptide optical and chemical isomers on the CFU-S population in intact and irradiated mice Deigin VI, Poverenny AM, Semenets TN, et al., International Immunopharmacology, 2007 · PMID 17276896

  The single most substantive internationally published paper on this molecule, and the source of the point that isomers are not interchangeable.

• [The replacement of accessory T-lymphocytes by synthetic peptides during the formation of splenic hematopoietic colonies] Semina OV, et al., Biulleten' Eksperimental'noi Biologii i Meditsiny, 1993 · PMID 8118007

  Earlier work in the same haematopoietic-progenitor tradition. Russian language.